A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 11 May 2017 Status changed from active, no longer recruiting to recruiting.
- 11 Apr 2017 Planned End Date changed from 23 Aug 2019 to 30 Jan 2019.
- 11 Apr 2017 Planned primary completion date changed from 1 Nov 2018 to 30 Jan 2019.